Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Munday

Surgery Danville, KY Medical Doctor

NPI 1245539022 CMS profile 1379297

130 Daniel Dr, Danville, KY 40422

Open in the dashboard

General payments

$270,545

356 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Munday of Danville, KY is reported in the CMS Open Payments database as having received $270,545 across 356 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22,267 32
2024 General $24,266 46
2023 General $56,035 75
2022 General $16,337 35
2021 General $49,370 51
2020 General $58,261 63
2019 General $44,010 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Munday
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to George Munday were reported at $22,267. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year George Munday Surgery median Middle half National median
2019 $44,010 $253 $82–$1,521 $163
2020 $58,261 $131 $40–$706 $114
2021 $49,370 $168 $50–$904 $132
2022 $16,337 $224 $76–$1,218 $149
2023 $56,035 $253 $82–$1,255 $160
2024 $24,266 $279 $90–$1,381 $164
2025 $22,267 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $225,992 227 payments
  2. W. L. Gore & Associates, Inc. $39,884 95 payments
  3. Heron Therapeutics, Inc. $4,109 8 payments
  4. Portola Pharmaceuticals, Inc. $86 4 payments
  5. Vertex Pharmaceuticals Incorporated $53 2 payments
  6. Davol Inc. $48 1 payment
  7. Myriad Genetic Laboratories, Inc. $46 2 payments
  8. Kowa Pharmaceuticals America, Inc. $43 1 payment
  9. Medtronic, Inc. $36 2 payments
  10. Pacira Pharmaceuticals Incorporated $35 2 payments
  11. Other $213 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $200,026 51 payments
  2. Consulting Fee $26,775 18 payments
  3. Food and Beverage $16,228 194 payments
  4. Travel and Lodging $10,010 75 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,808 15 payments
  6. Honoraria $7,700 3 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $225,992 227 payments
  2. GORE ENFORM Preperitoneal Biomaterial $14,121 34 payments
  3. GORE SYNECOR Biomaterial $13,885 41 payments
  4. SYNECOR Biomaterial $13,588 17 payments
  5. ZYNRELEF $4,109 8 payments
  6. GORE ENFORM Biomaterial $3,555 2 payments
  7. Product in Development $3,500 2 payments
  8. GORE BIO-A Tissue Reinforcement $3,489 6 payments
  9. BIO-A Tissue Reinforcement $3,475 5 payments
  10. SEAMGUARD Staple Line Reinforcement $332 8 payments
  11. Other $928 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

691

Median for General Surgery: 59

Drug cost

$5,637

Median for General Surgery: $393

Branded share of claims

38.1%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Hcl Generic 251 $2,782
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 224 $1,370
Lactulose Generic 11 $368
Omeprazole Generic 24 $233
Fluconazole Generic 18 $179
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 17 $165
Celecoxib Generic 21 $124
Neomycin Sulfate Generic 18 $103
Hydrocortisone Generic 15 $97
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 22 $62

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 103 billing codes

Paid by Medicare

$133,821

Medicare's payments for the services billed

Medicare patients

298

Average age 73

Services billed

743

137 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 37%
Diabetes 30%
Cancer 27%
Ischemic heart disease 24%
Atrial fibrillation 20%
Chronic kidney disease 20%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

356 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record